Comparative analysis of the latest box price of Lemborexant and prices in different channels
Lemborexant is a new type of dual-action melanin receptor antagonist, mainly used to treat adult insomnia. It can help patients improve their difficulty falling asleep and waking up at night. In 2019, the original drug Lebraxen was launched in the United States under the trade name Dayvigo. Subsequently, its original drug also entered the market in other countries. The domestic version of Lebrasin is marketed under the trade name "Daveco", but it has not yet been included in medical insurance, so patients need to bear all costs when purchasing.
In the domestic market, the price of the original drug Lebrasin is relatively high. The price of each box is about several thousand yuan depending on the specifications and sales channels. Since it is not covered by medical insurance, patients need to know the price and inventory of drugs in advance when purchasing them in hospital pharmacies or regular drug sales channels in order to arrange their medication plans reasonably. When prescribing medication, doctors usually develop individualized treatment plans based on the severity of the patient's symptoms and financial ability.
In overseas markets, the Japanese version of the original medicine is currently mainly sold, and the price is about RMB 1,000 per box. Generic drugs of Leborexan have not yet appeared in overseas markets, so patients can only choose to purchase the original drug. Although the price of purchasing drugs overseas is relatively cheap, transportation costs, drug storage conditions, and legal drug purchasing channels need to be considered to ensure drug quality and safety.
Generally speaking, Leborexan is already on the market in China but is not included in medical insurance, and the price is relatively high, while the overseas Japanese version of the original drug is relatively cheap, providing patients with a feasible choice. When choosing purchase channels, patients should comprehensively consider drug availability, price, legality and doctor's advice to ensure continuity of treatment and medication safety.
Reference materials:https://www.drugs.com/
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)